Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.

Yong Kyun KimHyoung Soo KimSunghoon ParkHwan-Il KimSun Hee LeeDong-Hwan Lee

Published in: The Journal of antimicrobial chemotherapy (2022)

ECMO use decreases piperacillin/tazobactam exposure. Prolonged or continuous infusion can achieve the treatment target in critically ill patients, particularly when MIC is above 8 mg/L or when patients have an eGFR of 130-170 mL/min/1.73 m2.

Keyphrases

extracorporeal membrane oxygenation
end stage renal disease
acute respiratory distress syndrome
ejection fraction
chronic kidney disease
low dose
patient reported outcomes
tyrosine kinase
epidermal growth factor receptor
respiratory failure
mechanical ventilation
patient reported